Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, Costa AF, Krpina K, Henrique R, Liberg AM, Rawat P, Gelebart P, McCormack E, Bjørge L, Davidson B, Greiff V, Costea DE, Pinto F, Flatmark K, Gomes C, Inderberg EM, Reis CA, Wälchli S(2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors Cell Rep Med, 102350(in press) DOI 10.1016/j.xcrm.2025.102350, PubMed 40925376
Andersson Y, Løvstakken E, Herud TM, Waagene S, Flatmark K, Fleten KG(2025) Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian Cancer Ann Surg Oncol(in press) DOI 10.1245/s10434-025-18025-x, PubMed 40788597
Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou Get al.(2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer Cancer Res, 85(5), 956-972 DOI 10.1158/0008-5472.CAN-24-0323, PubMed 39700396
